Sellas life sciences to present at the 66th american society of hematology (ash) annual meeting & exposition 2024

- presentation at ash will feature results from the phase 2a trial of sls009 in relapsed/refractory acute myeloid leukemia after venetoclax failure –

ASH Ratings Summary

ASH Quant Ranking